AMR-001: Phase II ongoing

NeoStem's Amorcyte LLC subsidiary said a DSMB recommended continuation of the double-blind, placebo-controlled, U.S. Phase II PreSERVE AMI trial of AMR-001 based on interim and safety data. The trial ...